• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

C. Light Launches AI-Driven Retinal Eye-Tracking; Predicts Neurological Health in 10 Seconds

by Jasmine Pennic 02/12/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
C.Light Launches AI-Driven Retinal Eye-Tracking; Predicts Neurological Health in 10 Seconds

– C. Light Technologies launches the world’s first AI-driven retinal eye-tracking technology to assess neurological health in the blink of an eye.

– The neurotech & AI company has the most sensitive tracker for eye motion on the cellular scale available today to predict neurological diseases in seconds.


C. Light Technologies, a Berkeley, CA-based neurotech and AI company participating in UC Berkeley’s premier accelerator SkyDeck, is introducing the world’s first retinal eye-tracking technology paired with machine learning to assess and predict neurological health. The technology is fast (10 seconds), non-invasive and objective.

Eye motion has been used for decades to quickly triage brain health. Now C. Light Technologies, a Berkeley SkyDeck neurotech, and AI company is measuring it down to the cellular level to monitor and track neurological diseases in seconds and determine how well medications are working.

Impact of Neurological Health on Americans

Neurological disorders like multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis (ALS), concussions, etc. affect millions of lives around the world. Neurological health is the fastest-growing area of healthcare costs. With about one million people with MS and six million with Alzheimer’s in the United States, neurodegenerative diseases cost the healthcare system $800 billion annually.

Additionally, diagnosing and monitoring these diseases is costly and time-consuming; and delaying diagnosis – combined with very limited medications available for treatment – creates even more challenges, symptoms and side effects for patients. Because of the speed of C. Light’s TSLO machine, doctors may very quickly see the state of the disease and determine how well a particular medication is working and make changes as needed.

AI-Driven Eye Tracking for Neurological Health

The C. Light solution is the world’s first retinal eye-tracking system that is 120 times more sensitive than other tracking systems available today. It can measure the motion of the eye on a cellular scale, movements as small as roughly 1/100 the size of human hair. The technique uses a Tracking Scanning Laser Ophthalmoscope (TSLO) developed by Dr. Christy Sheehy, founder of C. Light, which images the retina to better understand the conditions of the brain. C. Light’s solution is starting with multiple sclerosis (MS) and in the future will be used to assess or diagnose Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis (ALS) and concussions.

Unlike other techniques that can delay diagnosis and treatment, C. Light’s tech allows doctors to very quickly see the state of the disease and determine how well a particular medication is working and make changes as needed. The technology can help better manage a patient’s disease, and allow eye professionals like Stoney Eye Care to treat disease more effectively. Once a condition is confirmed, C. Light can be used to monitor and track progression.

“The back of your eye is actually the front of your brain. We use AI paired with eye tracking to create a digital fingerprint of your neurological health, with unprecedented speed and sensitivity,” said Dr. Zachary Helft, C. Light Co-Founder. “Other technologies use the pupil to track eye motion, but our technique images the retina for 120 times more sensitivity than the other tracking systems available today. In other words, C. Light measures eye motion that has been otherwise invisible through existing pupil tracking technologies.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: AI, Alzheimer’s disease, Eye Care, Machine Learning, medication, multiple sclerosis, neurodegenerative diseases, Premier

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |